CompletedPhase 3

A Trial of Efficacy, Safety and Tolerability of LVDS (Levonorgestrel Vaginal Delivery System) During 13 Cycles

Spain1,039 participantsStarted 2023-08-09

Plain-language summary

Multicentre, single arm phase III trial to assess the pearl index of LVDS. The trial lasts 13 cycles.The assessments include (but are not limited to) recording demographic data, pregnancy tests, gynaecological examinations, laboratory tests and a quality of life questionnaire. Adolescents will undergo DXA scans to measure bone mineral density (at selected sites only). The women will be provided with an e-diary app for their smartphone, to record IP use and vaginal bleeding.

Who can participate

Age range15 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Sexually active, postmenarcheal and premenopausal female subjects at risk of pregnancy including breastfeeding women.
✓. Women who either
✓. have never used hormonal contraceptives before consent/assent (naïve users), or
✓. have used hormonal contraceptives in the past, but have had a hormonal contraceptive-free period before consent/assent and a full menstrual cycle during the drug-free period (previous users) or
✓. directly switch from another hormonal contraceptive (switchers).
✓. Only for subjects who were not pregnant and did not use hormonal contraception during the last 6 months before consent/assent:

Exclusion criteria

✕. Pregnancy or wish of pregnancy.
✕. Subject is known to or suspected of not being able to comply with the trial protocol, the use of the trial medication or the use of the trial diary.
✕. History of infertility.
✕. Known bleeding disorder or history of unexplained bleeding or bruising within the last 12 months prior to V1a.
✕. Unexplained amenorrhoea.
✕. Abnormal finding on pelvic, breast or ultrasound examination that in the investigator's opinion contraindicates participation in the trial.

What they're measuring

Pearl Index

Timeframe: 1 year

Trial details

NCT IDNCT06019533

SponsorChemo Research

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-08-01

View on ClinicalTrials.gov More Contraception trials